BidaskClub upgraded shares of Advaxis, Inc. (NASDAQ:ADXS) from a hold rating to a buy rating in a research report released on Saturday.
ADXS has been the topic of several other reports. Cantor Fitzgerald reiterated an overweight rating and issued a $19.00 target price on shares of Advaxis in a report on Wednesday, May 31st. ValuEngine cut Advaxis from a sell rating to a strong sell rating in a report on Tuesday, August 8th. Finally, HC Wainwright set a $23.00 target price on Advaxis and gave the company a buy rating in a report on Wednesday, June 14th.
Advaxis (NASDAQ:ADXS) traded up 2.92% on Friday, reaching $7.41. 472,768 shares of the company traded hands. The stock’s market capitalization is $299.82 million. The firm has a 50 day moving average of $6.50 and a 200-day moving average of $7.54. Advaxis has a one year low of $5.70 and a one year high of $12.66.
ILLEGAL ACTIVITY WARNING: This article was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2017/09/10/advaxis-inc-adxs-upgraded-by-bidaskclub-to-buy.html.
Hedge funds have recently made changes to their positions in the stock. Stevens Capital Management LP bought a new stake in Advaxis in the first quarter valued at approximately $105,000. Voya Investment Management LLC boosted its holdings in Advaxis by 20.3% in the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 2,975 shares during the last quarter. Cutler Capital Management LLC bought a new stake in Advaxis in the second quarter valued at approximately $130,000. American International Group Inc. boosted its holdings in Advaxis by 7.6% in the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 1,459 shares during the last quarter. Finally, Northern Capital Management LLC boosted its holdings in Advaxis by 14.6% in the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 2,650 shares during the last quarter. Institutional investors and hedge funds own 48.78% of the company’s stock.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.